Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06799039 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease
A Early Phase 1 study, sponsored by Brigham and Women's Hospital.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 69
- Enrollment target
NCT06799039 is a Early Phase 1 study that has not yet begun recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 69 participants.
The verdict
NCT06799039, a Early Phase 1 study, has not yet begun recruiting, sponsored by Brigham and Women's Hospital.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
This 3+3 dose escalation pilot trial will assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in the Inflammatory Bowel Disease (IBD) patient population.
Interventions
- DRUG Xylitol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2031-09-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06799039
The ClinicalTrials.gov registry entry for NCT06799039 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Xylitol is the first listed.
NCT06799039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06799039 about?
NCT06799039 is a clinical study titled "Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease". This 3+3 dose escalation pilot trial will assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in the Inflammatory Bowel Disease (IBD) patient population.
What is the current status of trial NCT06799039?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 69 participants. The study started on 2026-09-01. Estimated completion is 2031-09-01.
What interventions are being tested in trial NCT06799039?
The interventions under investigation include: Xylitol (DRUG).
Who is sponsoring clinical trial NCT06799039?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.